TACE联合抗血管生成药治疗肝癌的研究进展  

Research progress of transarterial chemoembolization combined with anti-angiogenic drugs in the treatment of hepatocellular carcinoma

作　　者：刘欢丽 姜秋颖[1] LIU Huanli;JIANG Qiuying(The Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院,黑龙江哈尔滨150086

出　　处：《现代肿瘤医学》2022年第18期3408-3411,共4页Journal of Modern Oncology

摘　　要：肝癌是最常见、最致命的恶性肿瘤之一。肝动脉化疗栓塞(transarterial chemoembolization,TACE)是公认的肝癌非手术治疗中最常用的方法之一。TACE在阻断肿瘤组织血供的同时,也增加了肿瘤血管再生及形成侧支循环的风险。新生血管与恶性肿瘤的发生和发展关系密切。抗血管生成药能抑制血管内皮细胞的迁移和增殖,从而抑制肿瘤的生长。本文就TACE联合抗血管生成药治疗肝癌的进展进行综述。Hepatocellular carcinoma(HCC)is one of the most common and deadly malignancies.Transarterial chemoembolization(TACE)is recognized as one of the most commonly used methods for non-surgical treatment of hepatocellular carcinoma.TACE not only blocks the blood supply of tumor tissue,but also increases the risk of tumor angiogenesis and collateral circulation.Neovascularization is closely related to the occurrence and development of malignant tumors.Anti-angiogenic drugs can inhibit migration and proliferation of vascular endothelial cells,thereby inhibiting tumor growth.This article reviews the progress of TACE combined with anti-angiogenic drugs in the treatment of hepatocellular carcinoma.

关 键 词：肝癌 肝动脉化疗栓塞 抗血管生成药 

分 类 号：R735.7[医药卫生—肿瘤]